Epilepsy Research
Volume 28, Issue 1 , Pages 11-15, July 1997

Pharmacokinetics and muscle histopathology of intramuscular valproate

University of Miami, School of Medicine, 1150 N.W 14th Street, Miami, FL 33 101, USA

Received 17 February 1997; received in revised form 26 March 1997; accepted 27 March 1997.

Abstract 

To determine the safety and pharmacokinetics of parenteral sodium valproate healthy mature greyhound dogs, were given intramuscular injections following intravenous injections. Dosings intravenously and intramuscularly were at 20, 40 and 60 mg/kg in the three groups. Intravenous infusion rates were constant. Sodium valproate solution concentrations of 300, 400 and 500 mg/ml were administered. Intramuscular valproate was quickly absorbed. Bio-availability approached 70%. Half life of 120 min was calculated. Toxic muscle necrosis was observed at all concentrations. Dosing valproate intramuscularly in humans is problematic in view of the muscle damage. Despite tissue damage sodium valproate was well absorbed intramuscularly. The intravenous injection of valproate at high concentrations, large doses and fast infusion rates produced no evidence of cardiotoxicity and levels of 180 μg/ml.

Keywords:  Valproate, Intramuscular, Intravenous, Pharmacokinetic, Muscle necrosis, Inflammation

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0920-1211(97)00027-2

Epilepsy Research
Volume 28, Issue 1 , Pages 11-15, July 1997